home / stock / ncna / ncna message board
Subject | By | Source | When |
---|---|---|---|
I think we see $4 soon enough. By | bandit007 | investorshub | 07/25/2022 11:14:12 PM |
Agreed. GL | bandit007 | investorshub | 07/25/2022 11:10:50 PM |
This one is a no brainer. | Sociocobb | investorshub | 07/25/2022 7:57:05 PM |
Loaded heavy end of day. Looking forward to | bandit007 | investorshub | 07/25/2022 7:55:34 PM |
Undervalued even after the massive gains this month. | Sociocobb | investorshub | 07/18/2022 9:42:16 PM |
Going under a dollar. | willlbone | investorshub | 03/03/2022 8:14:26 PM |
Just my conjecture but the recent news gave | STEVEN52 | investorshub | 10/14/2021 4:15:10 PM |
Nah....that's not the reason...just look up the company...you'll | Marvy | investorshub | 10/14/2021 7:25:19 AM |
Increasing volume and upward trend over the past | STEVEN52 | investorshub | 10/14/2021 2:45:18 AM |
Could be a big pharma one day | Marvy | investorshub | 10/13/2021 8:01:16 PM |
NuCana Receives FDA Fast Track Designation For Acelarin | crudeoil24 | investorshub | 09/29/2021 12:11:01 PM |
Twice as many buys as sell on trading chart. | ktf7 | investorshub | 06/01/2020 5:30:58 PM |
NuCana Presenting at 2020 Jefferies Virtual Healthcare Conference | ktf7 | investorshub | 05/29/2020 1:57:56 AM |
NCNA Zacks Rank #1 Strong Buy | ktf7 | investorshub | 05/28/2020 6:53:58 PM |
It's interesting to know, thanks. | Manwaring | investorshub | 01/24/2020 2:58:14 PM |
Skip SANZERI Alersense | IHTZombies | investorshub | 07/24/2018 9:20:11 PM |
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthca...
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Ev...
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors ...